RT Journal Article
SR Electronic
T1 ESTIMATION OF COVID-19 CASES IN FRANCE AND IN DIFFERENT COUNTRIES: HOMOGENEISATION BASED ON MORTALITY
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.07.20055913
DO 10.1101/2020.04.07.20055913
A1 Dhenain, Marc
YR 2020
UL http://medrxiv.org/content/early/2020/05/13/2020.04.07.20055913.abstract
AB Every day the authorities of different countries provide an estimate of the number of persons affected by Covid-19 and a count of fatality. We propose to use the fatality reported in each country to provide a better estimate (Ct0-estimated) of the number of cases at a given time t0. With Ft0: number of fatalities reported in a country at time t0; Ft0: number of fatalities reported in a country at time t0 minus 3 days; Fr-est: estimated fatality rate. Based on Ct0-estimated calculated using a fatality rate of 2%, we assessed the number of cases April 10th, 2020 in Belgium, China, France, Germany, Iran, Italy, South Korea, Netherlands, Spain, United Kingdom and USA. This number reached 2,872,097 in France and 924,892 persons in Germany. This work suggests a very strong underestimation of the number of cases of people affected, with a notification index often lower than 5%. The proposed formulas also make it possible to evaluate the impact of policies to prevent the spread of epidemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received to perform this study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from: https://github.com/CSSEGISandData/COVID-19/tree/master/csse_covid_19_data/csse_covid_19_time_series https://github.com/CSSEGISandData/COVID-19/tree/master/csse_covid_19_data/csse_covid_19_time_series